12/24
06:15 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
12/23
07:01 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) was given a new $19.00 price target on by analysts at Chardan Capital.
Medium
Report
Kalaris Therapeutics (NASDAQ:KLRS) was given a new $19.00 price target on by analysts at Chardan Capital.
12/20
01:30 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at
Wall Stre
High
Report
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at
Wall Stre
12/18
06:08 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Kalaris Therapeutics (NASDAQ:KLRS) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/17
05:59 pm
klrs
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Medium
Report
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
12/17
04:01 pm
klrs
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
Low
Report
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
11/12
08:00 am
klrs
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Low
Report
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
11/3
09:03 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citizens Jmp. They set a "mkt outperform" rating and a $20.00 price target on the stock.
Medium
Report
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citizens Jmp. They set a "mkt outperform" rating and a $20.00 price target on the stock.
11/3
07:30 am
klrs
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Low
Report
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
11/3
05:02 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
Low
Report
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
10/30
08:00 am
klrs
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Low
Report
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
10/4
12:06 am
klrs
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at
Wall Stre
High
Report
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at
Wall Stre